ライフサイエンスコーパス: trough level

1 t, and were evaluated in relation to the MMF trough level.

2 the dose was adjusted to maintain the target trough level.

3 paradigm promoter P(purF) was locked at its trough level.

4 ions equivalent to maximal achievable plasma trough levels.

5 se of the day, whereas ccg-2 mRNA remains at trough levels.

6 n a significant decrease in the cyclosporine trough levels.

7 mg/kg b.i.d.; doses were titrated to target trough levels.

8 s adjusted to achieve comparable whole-blood trough levels.

9 evels could be drawn, or incorrect timing of trough levels.

10 tacept with lowered tacrolimus and sirolimus trough levels.

11 with lower Tac, but not CsA, dose-normalized trough levels.

12 us were necessary for maintaining sufficient trough levels.

13 is clinically useful even in the absence of trough levels.

14 ll P<0.001) but did not correlate with mTORi trough levels.

15 LCPT requires lower doses to achieve target trough levels.

16 on between LCP-Tacro tacrolimus exposure and trough levels.

17 Vancomycin dose was adjusted on the basis of trough levels.

18 ration of SEP-225289, to assess occupancy at trough levels.

19 ng/mL); or convert to "reduced" TAC (target trough level 3.0-5.9 ng/mL) or "standard" TAC (target tr

20 and 2927 mg/y [IQR, 2377 to 3667 mg/y]) and trough levels (4.2 microg/mL [IQR, 2.6 to 5.8 microg/mL]

21 a 45-day course of intravenous cyclosporine (trough level 400-800 ng/ml).

22 tly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than

23 received steroids, reduced-dose CsA (target trough level 50% of full-dose range), and 1, 3, or 5 mg/

24 vel 3.0-5.9 ng/mL) or "standard" TAC (target trough level 6.0-8.9 ng/mL).

25 and 24 h after reperfusion), and tacrolimus (trough levels 8-12 ng/mL) was used for maintenance immun

26 t HIV-1 protease inhibitors maintain in vivo trough levels above their human serum protein binding-co

27 The median steady-state trough level achieved after dose escalation was 331 ng/m

28 who received enoxaparin adjusted by anti-Xa trough level (adjustment group) were compared with those

29 prednisone or tacrolimus dose or tacrolimus trough level and either the PD-L1/CD86 ratio on plasmacy

30 immunosuppressive drug (tacrolimus) dose or trough level and HLA-G expression or Treg frequency or F

31 Long-term target TAC trough level and MMF dosing were 5 to 7 ng/mL and 1,000

32 Adalimumab trough level and PASI score at the time of serum samplin

33 on sirolimus adjusted to a target rapamycin trough level and reduced-dose cyclosporine adjusted to t

34 Correlations between 12 h trough levels and AUC were r = 0.917 for generic tacroli

35 ombination therapies including MMF, at serum trough levels and higher, are toxic for the human bronch

36 Tacrolimus trough levels and laboratory values were closely monitor

37 year postoperatively, with lower tacrolimus trough levels and no difference in other adverse events.

38 nDSA) development correlates with tacrolimus trough levels and the recipient's individualized alloimm

39 crolimus (0.15 mg/kg/day; 10-15 ng/mL target trough levels) and a tapered dose regimen of steroids.

40 ative immune induction, average cyclosporine trough level, and HLA mismatch.

41 The mean Tac dose, 12-hr trough level, and percentage of patients receiving maint

42 -ME dose reduction to maintain preconversion trough levels, and 64% of the patients attained their Cs

43 that HLA-DR/DQ eplet mismatch and tacrolimus trough levels are independent predictors of dnDSA develo

44 ulative data show that dose requirements and trough levels are similar between brand and generic tacr

45 icates that certain PK parameters, including trough levels, are correlated with clinical outcomes for

46 t patients who had routine monitoring of MMF trough level at the time of scheduled endomyocardial bio

47 then concentration-controlled to keep 24-hr trough levels at 10 to 12 ng/mL for 6 months and 5 to 10

48 , incidence of delay graft function, and Tac trough levels at different time points after transplanta

49 The mean (+/- SD) CsA trough levels at end point were 187 +/- 63 and 210 +/- 9

50 higher MMF exposure and elevated tacrolimus trough levels at M3.

51 ONCLUSION In patients with advanced GIST, IM trough levels at SS were associated with clinical benefi

52 nd clinical outcomes were correlated with IM trough levels at SS.

53 Mean trough levels at week 24 in the IV infusion series of 30

54 TAC trough levels at week two posttransplant were significan

55 sttransplant year, with (1) at least 3 blood trough levels available to calculate coefficient of vari

56 hin each race stratum, the mean cyclosporine trough levels averaged over 2-week intervals were nearly

57 initiated, the TAC dosage was skipped until trough levels began to decline; it was then administered

58 We analyzed the frequency of tacrolimus trough levels below a series of thresholds <6 ng/ml and

59 Levels of CsA were adjusted to maintain trough levels between 400 and 800 ng/ml.

60 nversion tacrolimus dose at each visit; mean trough levels between groups were similar.

61 Three measurements of CsA trough level, blood pressure, serum creatinine concentra

62 characterized by high peak and undetectable trough levels, both of which are required for male-speci

63 ine whether targeting a prophylactic anti-Xa trough level by adjusting the enoxaparin dose would redu

64 m level of uric acid, and blood cyclosporine trough level (C0) and used higher doses of cyclosporine

65 m level of uric acid, and blood cyclosporine trough level (C0) and used higher doses of cyclosporine

66 late and vitamin B12, and blood cyclosporine trough level (C0) are independently associated with tHcy

67 which is reflected in a rise of the predose trough level (C0).

68 3), and BUN (P=0.05), and blood cyclosporine trough level (C0, P=0.005) were independently associated

69 ents not infected with HIV, tacrolimus (TAC) trough levels (C0) or cyclosporine (CsA) drawn at C0 or

70 Mean TAC trough level (Cmin), used to adjust daily dose, was not

71 bulation), hospital discharge before initial trough levels could be drawn, or incorrect timing of tro

72 Patients received EVL (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacro

73 (2) Trough levels did not differ between monotherapy and sta

74 Careful monitoring of tacrolimus trough levels during concomitant chloramphenicol therapy

75 dme-miR-263a and -263b reach trough levels during the daytime, peak during the night

76 tentially meaningful changes in cyclosporine trough levels early in the postconversion course were us

77 ), an increased exposure might occur without trough levels exceeding the target range, resulting in "

78 he incidence of rejection in relation to MMF trough level following heart transplantation.

79 rejection was noted in the samples with MMF trough level > or = mg/l compared to those with less tha

80 Ninety-six percent had at least 1 trough level >/=100 U/L.

81 Evl trough levels > or =3 ng/mL plus Tac are associated with

82 vo with concentration-controlled Evl (target trough levels > or =3 ng/mL) plus low-dose Tac or Evl pl

83 EVR trough levels >8 ng/mL were significantly associated wit

84 1.31]) compared to "conventional tacrolimus" trough levels (>10 ng/mL).

85 ant recipients with 50,011 serial tacrolimus trough levels had HLA-DR/DQ eplet mismatch determined us

86 Similar to younger recipients TAC trough level has also a high correlation (R = 0.76) with

87 ed by daily weights, chest radiographs, drug trough levels (high-performance liquid chromatography/ma

88 ightly, adjusted according to serum anti-HBs trough level) if they were HBsAg- and HBV-DNA negative a

89 clinically significant decrease in CsA 12-hr trough levels immediately after the institution of trogl

90 staggered group were the same or lower than trough levels in animals treated with either drug alone

91 atients with serum creatinine >3.0 mg/dl had trough levels in excess of the population mean (T: range

92 le therapy was implemented for 120 days, and trough levels in serum were within or above the suggeste

93 Mean tacrolimus trough levels in the 6 months before dnDSA development w

94 Target SDZ RAD trough levels in the CTL group (no mAb) were 20-40 ng/ml

95 ariable analysis, high calcineurin inhibitor trough levels in the month before diagnosis (odds ratio

96 RAD and CsA day-14 trough levels in the staggered group were the same or lo

97 Trough levels increased from 45 to 132 ng/ml (P<0.001).

98 ther increased to 6045 ng h/ml (P=0.03), and trough levels increased to 218 ng/ml (P=0.03), above the

99 The C1-INH trough levels increased with C1-INH treatment.

100 Tacrolimus trough levels increased, and the dose was adjusted to ma

101 sodium is dosed by anti-factor Xa (anti-Xa) trough level is not well described.

102 he determination of optimal tacrolimus (TAC) trough levels is needed to prevent adverse effects of ca

103 eiving C1H/Tac, patients with an average Tac trough level less than 6.5 ng/mL during the first 2 mont

104 s to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more

105 s > or = 2 mg/l compared to samples with MMF trough level <2 mg/l (3.6% vs. 14.4%, P=0.005).

106 dnDSA had a higher proportion of tacrolimus trough levels <5 ng/ml, which continued to be significan

107 We compared maximum 12-hr tacrolimus trough levels (MaxC0) and dose-adjusted MaxC0 in 12 case

108 Monitoring of MMF trough levels may play a role in the management of cardi

109 y weight assessment, chest radiographs, drug trough levels measured by high-performance liquid chroma

110 the steady-state drug exposure with a single trough-level measurement.

111 te rejection before month 3 (M3), tacrolimus trough levels more than 10 ng/mL, and M3 AUC0-12 hr more

112 y; day 8-28: 100 mg/kg/day; n=6; mean +/- SE trough level (MTL): 292+/-17 ng/ml) or SDZ RAD monothera

113 Patients with a trough level of 0.1 IU/mL or lower received enoxaparin s

114 ofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 microg/ml) or CsA (target trough

115 adjusted over time to maintain a whole-blood trough level of 12-15 ng/ml at 0-1 month, 10-12 ng/ml at

116 dosed twice daily to maintain a 12-hour drug-trough level of 150 ng/mL.

117 ned randomly (1:1:1) to continue CsA (target trough level of 50-250 ng/mL); or convert to "reduced" T

118 nd given a sirolimus dose to achieve a 24-hr trough level of 8 to 14 ng/mL.

119 h level of 1.5-2.5 microg/ml) or CsA (target trough level of 80-100 ng/ml) in 60 pediatric patients w

120 At day 7 the blood trough level of FK506 in the FK506 group was 10-fold hig

121 antly lower rates of BPAR as compared with a trough level of less than 3 ng/mL.

122 Evl trough level of more than or equal to 3 ng/mL was associ

123 The targeted trough level of tacrolimus was between 8 and 10 ng/mL fo

124 icant graft survival occurred at whole blood trough levels of 0.5 ng/ml achieved at the 0.3 mg/kg/day

125 +/- 364 pg/mL (endogenous TPO) to predosing trough levels of 1, 840 +/- 353 pg/mL PEG-rHuMGDF (P = .

126 Sirolimus was increased to maintain trough levels of 12-15 ng/mL.

127 imen adjusted daily to maintain target 24 hr trough levels of 150-300 ng/ml CsA for poday 0 to poday

128 , Switzerland) and sirolimus with target CsA trough levels of 225 and 175 ng/mL at 1 month and 1 year

129 A therapeutic range of adalimumab trough levels of 3.51 mg/L to 7.00 mg/L, which correspon

130 0 +/- 300 pg/mL 2 hours after injection with trough levels of 300 +/- 65 pg/mL before the next dose.

131 Maintenance target 12-hr tacrolimus trough levels of 5 to 7 ng/mL were operational from the

132 500 mg twice daily) and tacrolimus (targeted trough levels of 5 to 7 ng/ml) and no corticosteroid the

133 g at 3mg/m(2) /day (titrated to target blood trough levels of 5-15ng/ml).

134 ith dose adjustments to maintain whole blood trough levels of 8-15 ng/mL by IMx.

135 ensitivity to PEGasparaginase had serum mean trough levels of 899 U/L.

136 uppression was reduced to achieve tacrolimus trough levels of approximately 8 ng/mL and prednisone at

137 nt between mice UV-irradiated during peak or trough levels of cyclosporine in the blood.

138 pigs had greater T cell depletion and higher trough levels of cyclosporine.

139 Trough levels of FK506 were not predictive for the devel

140 Patients were closely monitored for trough levels of immunosuppressive agents, laboratory va

141 (BP), hemoglobin, serum creatinine, lipids, trough levels of immunosuppressive drugs, and daily prot

142 Patients with very low trough levels of less than 4 g/L had poor clinical outco

143 s have significantly (P=0.001) higher 1-year trough levels of mycophenolic acid (4.16 ng/mL) than cyc

144 Pronounced elevations in trough levels of nitric oxide metabolites occurred with

145 stem recovered bacteria only in bottles with trough levels of piperacillin-tazobactam.

146 The 12-hour trough levels of tacrolimus were significantly higher in

147 Trough levels of tacrolimus were significantly lower in

148 e similar doses of corticosteroids and lower trough levels of tacrolimus, compared with 15% of white

149 No correlation between ribavirin trough level on day 7 or at month 2 with a virological r

150 eater incidence of subtherapeutic tacrolimus trough levels on postoperative day 7.

151 tes differed among the quartiles of imatinib trough levels (P = .01 for CCyR, P = .02 for MMR).

152 hich correlated with undetectable adalimumab trough levels (P = 0.014).

153 s observed between AAA titers and adalimumab trough levels (P = 0.2).Concomitant immunosuppression di

154 Trough level plasma samples were obtained on day 29 (ste

155 Target tacrolimus trough levels postoperatively were 10, 8, and 6 ng/mL at

156 day 105 correlated inversely with sirolimus trough levels (R2=0.67, P<0.05).

157 re maintained on tacrolimus monotherapy with trough levels ranging between 4 and 12 ng/mL.

158 Because SD increased as mean trough levels rose, CV% (CV%=SD/mean multiplied by 100%)

159 Initial and 3- to 6-month cyclosporin A trough level targets were 250 to 300 and 225 to 275 ng/m

160 nts on ritonavir-containing cART and raising trough levels to achieve an exposure equivalent to HIV-n

161 Groups were stratified by both Evl and Tac trough levels to evaluate glomerular filtration rate and

162 to correlate the risk of proteinuria to EVR trough levels up to 24 months posttransplant.

163 Sirolimus remained > 5 mug/L, the trough level used in oral immunosuppressive therapy, for

164 f rejection decreased significantly when MMF trough level was > or = 2 mg/l compared to samples with

165 However, in group B, the target tacrolimus trough level was 4 to 7 ng/mL to reduce long-term nephro

166 Imatinib plasma trough level was performed at day 22 and if <1000 ng/mL,

167 roviding 3 adjusted doses of enoxaparin, the trough level was redrawn and the dosage was adjusted as

168 oups, despite the fact that the mean SDZ RAD trough level was significantly lower in the CD25 group (

169 Mean prednisone dose and cyclosporine trough level were higher in the women than the men (P<0.

170 Target tacrolimus trough levels were 10 and 8 ng/mL at 1 month and 1 year,

171 Target CsA trough levels were 100-200 ng/ml.

172 ) than preconversion tacrolimus dose; target trough levels were 4-15 ng/mL.

173 Maintenance sirolimus target trough levels were 8 ng/mL in groups A and C.

174 Tacrolimus trough levels were 9.3+/-2.4 ng/ml (off steroids) and 9.

175 L had poor clinical outcomes, whereas higher trough levels were associated with a reduced frequency o

176 Deviations in trough levels were avoided, thus preventing any clinical

177 ance: In this study, subprophylactic anti-Xa trough levels were common in trauma patients.

178 Baseline characteristics and mean tacrolimus trough levels were comparable between arms.

179 henolate mofetil dose nor tacrolimus dose or trough levels were different between those with or witho

180 serum daclizumab and mycophenolic acid (MPA) trough levels were evaluated.

181 Overall, adalimumab trough levels were higher in responder patients.

182 The target 12-hr Tac trough levels were lowered to 4 to 6 ng/mL in the signif

183 Tacrolimus (TAC) and mycophenolic acid (MPA) trough levels were measured from 1 to 12 months posttran

184 Exposures: Anti-Xa trough levels were monitored in patients in the adjustme

185 Trough levels were monitored.

186 Steady-state trough levels were obtained after 6 weeks of therapy; pa

187 loratory analysis demonstrated that imatinib trough levels were predictive of higher CCyR independent

188 Tacrolimus trough levels were readily achieved posttransplant; init

189 SIR doses and trough levels were significantly higher in the SIR-LD pa

190 ter the first year posttransplant, CsA 12-hr trough levels were significantly lower in late rejection

191 ted in HIV-negative recipients, when similar trough levels were targeted.

192 ed on LCP-Tacro once-daily for days 8 to 21; trough levels were to be maintained between 5 and 15 ng/

193 rences in tacrolimus exposure in the 2 arms; trough levels were toward the upper end of the low-expos

194 Neoral resulted in significantly higher LFM trough levels when compared to LFM monotherapy.

195 There were no differences in mean doses or trough levels when comparing the two study groups.

196 Therapeutic monitoring is based on mTORi trough levels, which do not necessarily reflect biologic

197 uration of dose-corrected tacrolimus predose trough levels with time after transplantation.

198 patients with therapeutic immunosuppressive trough levels, with or without first inducing ACR.

199 old immediately before each meal and fell to trough levels within 1 h after eating, a pattern recipro

200 Lack of variation of 5-FU trough levels within a day at steady-state indicates sup